Not known Facts About Imipenem
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Major demo objectives had been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyosi